Advances in Hematology
Overview
Advances in Hematology is a scientific journal, published by Wiley since 2008 in English. The journal's country of origin is United States and its primary focus area is hematology.
Details
Details
Abbr.
Adv Hematol
Publisher
Wiley
Start
2008
End
Continuing
p-ISSN
1687-9104
e-ISSN
1687-9112
Country
United States
Language
English
Specialty
Hematology
Metrics
Metrics
h-index / Ranks: 9030
38
SJR / Ranks: 8161
553
CiteScore / Ranks: 7633
3.50
Recent Articles
1.
Hershberger D, Samson K, Saeed M
Adv Hematol
. 2025 Jan;
2024:3616532.
PMID: 39764354
Sepsis is a major cause of mortality worldwide. Early identification and treatment are critical to improve survival. Band count has been used as part of SIRS criteria for the early...
2.
Scott J, Christian J, Plazas Montana M, Miller Y, Naik R
Adv Hematol
. 2024 Dec;
2024:3854629.
PMID: 39735783
Universal in the United States (US) since 2006, newborn screening (NBS) programs for sickle cell disease (SCD) allow for early identification of the disease and, as an unintentional byproduct, identification...
3.
Koffi K, Bognini S, Silue D, Kamara I, Kouakou I, Ndhatz E, et al.
Adv Hematol
. 2024 Dec;
2024:4576455.
PMID: 39698378
The present study aimed to evaluate for the first time, the early molecular response (EMR) to imatinib at 3 months for patients with chronic myeloid leukemia and to determine the...
4.
Parrow N, Doherty J, Conrey A, Thein S, Fleming R
Adv Hematol
. 2024 Dec;
2024:9872440.
PMID: 39659429
Based on the relationship between the intracellular concentration of sickle hemoglobin S (HbS) and the delay that occurs prior to the onset of sickling following deoxygenation, targeting the intracellular HbS...
5.
Kene-Udemezue B, Salako A, Akinsete A, Odubela O, Adeyemo T
Adv Hematol
. 2024 Dec;
2024:5002373.
PMID: 39624343
Hydroxyurea (HU) is a disease-modifying therapy with significant clinical and laboratory efficacy among individuals living with sickle cell anaemia (SCA). This is evident through increased fetal haemoglobin, higher packed cell...
6.
Alfaifi A, Bahashwan S, Alsaadi M, Ageel A, Ahmed H, Fatima K, et al.
Adv Hematol
. 2024 Nov;
2024:5948170.
PMID: 39563886
Lymphoma is the sixth most prevalent cancer globally. Non-Hodgkin's lymphomas are the majority group of lymphomas, with B cells accounting for approximately 95% of these lymphomas. A key feature of...
7.
Ndoumba A, Chendjou Kamela A, Wamba C, Azebaze Agueguia F, Carolle N, Tayou Tagny C, et al.
Adv Hematol
. 2024 Sep;
2024:6660891.
PMID: 39234427
Introduction: In Cameroon, screening and diagnosis of minor hemorrhagic syndromes remain difficult and few research studies have been done to assess the magnitude of future bleeding risk and the burden...
8.
Roessner C, Sale T, Uminski K, Goodyear D, Rydz N
Adv Hematol
. 2024 Jun;
2024:4753349.
PMID: 38912090
Sickle cell disease (SCD) is a common genetic disorder with potentially serious sequelae that can be effectively treated with hydroxyurea. Despite its favorable benefit-risk profile, hydroxyurea uptake in patients with...
9.
Aldecoa K, Arsene C, Krishnamoorthy G, Chng T, Cherry G, Chowdhury N, et al.
Adv Hematol
. 2024 Jun;
2024:1595091.
PMID: 38899005
Pregnant women and individuals with sickle cell trait (SCT) and underlying comorbidities are both independently more vulnerable to severe illness from coronavirus disease 2019 (COVID-19) compared to nonpregnant women and...
10.
Hambalie A, Norahmawati E, Endharti A, Retnani D, Rahmadiani N
Adv Hematol
. 2024 May;
2024:7989996.
PMID: 38817669
Background: Lymphomas are malignant lymphocyte neoplasms that globally account for 10% of cancers in individuals aged <20 years. Malignant lymphomas are divided into Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL)....